Anita Cervantes, APRN
Nurse Practitioner · Katy, TXNPI 1457989998
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 100.0% of the total across 13 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. 8 manufacturers reported payments, led by AstraZeneca at 31.8% of the total. 2025 is the largest year on record at $475, 2.2 times the $216 reported in 2022.
Across 13 payments — averaging $88.49 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AstraZeneca$366
- Gilead$209
- Sanofi$122
- Inari Medical, Inc.$116
- Teva Pharmaceuticals USA, Inc.$110
- GSK$99
- plus $129 from 2 others
What the payments were for
- Food & beverage$1,150100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AstraZeneca | 4 | $366 |
| Gilead | 2 | $209 |
| Sanofi | 1 | $122 |
| Inari Medical, Inc. | 1 | $116 |
| Teva Pharmaceuticals USA, Inc. | 1 | $110 |
| GSK | 1 | $99 |
| Mylan Specialty L.p. | 1 | $94 |
| Pfizer | 2 | $35 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- AIRSUPRA$242
- Livdelzi$122
- CERDELGA$122
- CEREZYME$122
- FABRAZYME$122
- BREZTRI$117
- FLOWTRIEVER CATHETER, S$116
- CT THROMBECTOMY SYSTEM KIT$116
- UZEDY$110
How this compares
$1,150 in reported general payments places this provider in the 80th percentile of 5,422 nurse practitioner providers in Texas.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Cefdinir | 14 | $302 |
| Methylprednisolone | 17 | $118 |
| Amoxicillin-Clavulanate PotassAmoxicillin/Potassium Clav | 19 | $116 |
| Azithromycin | 25 | $108 |
| Ibuprofen | 20 | $39 |
| Prednisone | 23 | $36 |
| Acetaminophen-CodeineAcetaminophen With Codeine | 11 | $34 |
| Naproxen | 12 | $17 |
Paid to pharmacies, not to this prescriber.
Other nurse practitioner in Katy
- Cecilia DavisAustin$262K
- Melanie MorrisHouston$254K
- Stephanie BrownHarlingen$235K
- Brittney MisercolaKilleen$223K
- Roger ChapmanTyler$211K
- Corrie BerkSan Antonio$155K
- Samantha OnealDallas$133K
- Onna FeuchterSouthlake$108K
- Stephanie AgrellaRound Rock$102K
- Sue RankinAmarillo$89K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.